Could a gentle pill stop blood cancer before it starts?
NCT ID NCT07435636
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a low-dose oral drug (decitabine with tetrahydrouridine) in 80 adults aged 60–85 who have a high-risk blood condition called CCUS, which often leads to blood cancer. The drug aims to reduce harmful mutations in blood cells and restore normal blood production without the harsh side effects of standard cancer treatments. Participants will receive either the drug or a placebo for 24 weeks to see if it can safely prevent disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CCUS CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Canberra Health Services
Canberra, Australian Capital Territory, 2605, Australia
-
Prince of Wales Hospital
Randwick, New South Wales, 2031, Australia
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a walking routine alter cancer biomarkers? new trial investigates
- Fiber fix: could a Plant-Based diet boost Well-Being in blood condition?
- New registry aims to unlock secrets of rare blood cancers
- Massive study aims to unlock secrets of rare Cancer-Predisposing gene
- Can a single drug boost blood counts and delay cancer in High-Risk patients?
- New drug aims to boost blood counts in rare pre-leukemia condition